As the metaverse, the next iteration of the internet that encompasses and converges virtual reality (VR) and physical reality in the digital space, promises to change the experience of stakeholders across the healthcare sector, pharma appears keen to be part of what could be the next big thing.
GSK CTO, Boehringer Exec On The Metaverse And Pharma’s Foot In The Door
GSK Has Seen ' Lot Of Success' With Bots
Big pharma executives discuss the transformative potential of the metaverse in the life sciences segment and how things are shaping in the virtual world amid the hype. GSK’s senior VP and chief technology officer outlines to Scrip gains made deploying digital twins and bots.
More from Business
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.